Verrou Evgenia, Diamanti Ioanna, Fylaktou Asimina, Daiou Aikaterini, Dalampira Dimitra, Dimitriadou Xanthippi, Tara Vassiliki, Karadrakonti Elissavet, Triantafyllou Theodora, Sevastoudi Aggeliki, Vlachaki Efthimia, Karampatzakis Nikolaos, Papadopoulou Theodosia, Sinakos Emmanouil, Katodritou Eirini, Gioula Georgia
Hematology Department, Theagenio Cancer Hospital, Thessaloniki, Greece.
Biochemistry and Microbiology Department, Theagenio Cancer Hospital, Thessaloniki, Greece.
Front Oncol. 2025 Jun 24;15:1586454. doi: 10.3389/fonc.2025.1586454. eCollection 2025.
The sequential occurrence of diffuse large B-cell lymphoma (DLBCL) in a patient diagnosed with classical Hodgkin lymphoma (cHL) or vice versa represents a rare situation. In parallel, human leukocyte antigen (HLA) has been studied extensively about rising susceptibility in various lymphomas. Herein, we present clinical characteristics, the outcome and the results of HLA class-I and class-II investigation in patients sequentially diagnosed with the above-mentioned combination of lymphomas. We describe 8 patients (6 males/2 females) with median age at diagnosis of first and second lymphomas of 45.5 years (range: 25-74 years) and 57.5 years (range: 30-83 years), respectively. The median interval between the first and the second diagnosis was 6.5 years (range: 4-22 years). Regarding HLA investigation, we observed that four of our patients were HLA-DQB103:01 positive. Interestingly, three of our patients displaying this HLA allele developed a third lymphoma. Notably, we observed that the HLA profile of three other patients revealed the presence of HLA-B35:03. Interestingly, both above-mentioned HLA alleles have been associated with autoimmune manifestations. Although the presence of certain HLA alleles in our patients could be coincidental, our results suggest that HLA typing may be a field of investigational interest regarding patients with sequential lymphomas.
在已诊断为经典型霍奇金淋巴瘤(cHL)的患者中相继发生弥漫性大B细胞淋巴瘤(DLBCL),或者反之亦然,这是一种罕见的情况。与此同时,人类白细胞抗原(HLA)在各种淋巴瘤易感性增加方面已得到广泛研究。在此,我们呈现了相继诊断为上述淋巴瘤组合的患者的临床特征、结局以及HLA I类和II类检测结果。我们描述了8例患者(6例男性/2例女性),首次和第二次淋巴瘤诊断时的中位年龄分别为45.5岁(范围:25 - 74岁)和57.5岁(范围:30 - 83岁)。第一次和第二次诊断之间的中位间隔时间为6.5年(范围:4 - 22年)。关于HLA检测,我们观察到4例患者HLA - DQB103:01呈阳性。有趣的是,携带这种HLA等位基因的3例患者发生了第三种淋巴瘤。值得注意的是,我们观察到另外3例患者的HLA谱显示存在HLA - B35:03。有趣的是,上述两种HLA等位基因都与自身免疫表现有关。虽然我们患者中某些HLA等位基因的存在可能是巧合,但我们的结果表明,对于相继发生淋巴瘤的患者,HLA分型可能是一个值得研究的领域。